Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIA: Added effects of aliskiren on albuminuria in non-diabetic nephropathy
2009-012196-10Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of aliskiren in chronic kidney disease (CKD) (2 arms), sponsored by Novartis. Primary endpoint: Change in albuminuria. Started Apr 2010; status: terminated.
02
Drugs
aliskiren
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2009-012196-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012196-10.